Article Text

Download PDFPDF
Discontinuing risperidone results in relapse in children with autism spectrum disorders

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

OpenUrlCrossRefPubMedWeb of Science

Q Does risperidone prevent relapse compared with placebo for children with autism spectrum disorders?


Embedded ImageDesign:

Randomised controlled trial.

Embedded ImageAllocation:


Embedded ImageBlinding:

Double blind.

Embedded ImageFollow up period:

Thirty two weeks.

Embedded ImageSetting:

Groningen and Utrecht University Child and Adolescent Psychiatry Centres; time period not stated.

Embedded ImagePatients:

Thirty six children aged 5–17 years with an autism spectrum disorder (Autism Diagnostic Interview-Revised plus clinical judgement) enrolled in the open label phase, 24 children who responded to risperidone were randomised. Other enrolment criteria: at least moderate disruptive behaviour (tantrums, self-injury, and/or aggression) …

View Full Text


  • For correspondence: Dr Pieter W Troost, Child and Adolescent Psychiatry Center, Hanzeplein 1, 9713 GZ Groningen, the Netherlands; p.troost{at}

  • Source of funding: Korczak Foundation.